Unsere Publikationen

Comparing the long-term clinical and economic impact of ofatumumab versus dimethyl fumarate and glatiramer acetate in patients with relapsing multiple sclerosis: A cost-consequence analysis from a societal perspective in Germany

Link
https://doi.org/10.1177/20552173221085741
Tags
Multiple SkleroseMS Behandlung
Jahr
2022
Autoren
Koeditz D, Frensch J, Bierbaum M, Ness NH, Ettle B, Vudumula U, Gudala K, Adlard N, Tiwari S, Ziemssen T.
Verlag
Mult Scler J Exp Transl Clin. 2022 Mar 29;8(1):20552173221085741.
Zum Eintrag

Efficacy of prolonged-release fampridine versus placebo on walking ability, dynamic and static balance, physical impact of multiple sclerosis, and quality of life: an integrated analysis of MOBILE and ENHANCE

Link
https://doi.org/10.1177/17562864221090398
Tags
Multiple SkleroseMS BehandlungMobilität
Jahr
2022
Autoren
Hupperts R, Gasperini C, Lycke J, Ziemssen T, Feys P, Xiao S, Acosta C, Koster T, Hobart J.
Verlag
Ther Adv Neurol Disord. 2022 May 18;15:17562864221090398.
Zum Eintrag

Current status and new developments in sphingosine-1-phosphate receptor antagonism: fingolimod and more

Link
https://doi.org/10.1080/17425255.2022.2138330
Tags
Multiple SkleroseMS Behandlung
Jahr
2022
Autoren
Constantinescu V, Akgün K, Ziemssen T.
Verlag
Expert Opin Drug Metab Toxicol 2022;18(10):675-693.
Zum Eintrag

Assessing the immune response to SARS-CoV-2 mRNA vaccines in siponimod-treated patients: a nonrandomized controlled clinical trial (AMA-VACC)

Link
https://doi.org/10.1177/17562864221135305
Tags
Multiple SkleroseMS BehandlungNeuroimmunologie
Jahr
2022
Autoren
Ziemssen T, Groth M, Rauser B, Bopp T.
Verlag
Ther Adv Neurol Disord 2022;15.
Zum Eintrag

S1P receptor modulators and the cardiovascular autonomic nervous system in multiple sclerosis: a narrative review

Link
https://doi.org/10.1177/17562864221133163
Tags
Multiple SkleroseMS BehandlungAutonomes Nervensystem & NeuroendokrinologieHerzratenvariabilität
Jahr
2022
Autoren
Constantinescu V, Haase R, Akgün K, Ziemssen T.
Verlag
Ther Adv Neurol Disord. 2022 Nov 22;15:17562864221133163.
Zum Eintrag

Safety of Fingolimod in Patients with Multiple Sclerosis Switched from Natalizumab: Results from TRANSITION―A 2-Year, Multicenter, Observational, Cohort Study

Link
https://doi.org/10.3390/brainsci12020215
Tags
Multiple SkleroseMS Behandlung
Jahr
2022
Autoren
Butzkueven H, Giacomini PS, Cohan S, Ziemssen T, Sienkiewicz D, Zhang Y, Geissbühler Y, Silva D, Tomic D, Kropshofer H, Trojano M.
Verlag
Brain Sci. 2022 Feb 4;12(2):215.
Zum Eintrag

CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis

Link
https://doi.org/10.1177/13524585211032803
Tags
Multiple SkleroseMS Behandlung
Jahr
2022
Autoren
Comi G, Dadon Y, Sasson N, Steinerman JR, Knappertz V, Vollmer TL, Boyko A, Vermersch P, Ziemssen T, Montalban X, Lublin FD, Rocca MA, Volkinshtein R, Rubinchick S, Halevy N, Filippi M.
Verlag
Mult Scler. 2022 Apr;28(4):608-619.
Zum Eintrag

Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data

Link
https://doi.org/10.1177/13524585211061335
Tags
Multiple SkleroseMS Behandlung
Jahr
2022
Autoren
Coles AJ, Jones JL, Vermersch P, Traboulsee A, Bass AD, Boster A, Chan A, Comi G, Fernández Ó, Giovannoni G, Kubala Havrdova E, LaGanke C, Montalban X, Oreja-Guevara C, Piehl F, Wiendl H, Ziemssen T.
Verlag
Mult Scler. 2022 Apr;28(5):842-846.
Zum Eintrag
5 6 7 8 9

Publikationen durchsuchen

Publikationen filtern

Filters
Tags
Multiple Sklerose
MS Behandlung
Mobilität
Autonomes Nervensystem & Neuroendokrinologie
Neuroimmunologie
Herzratenvariabilität
Baroreflexsensitivität
Management & Science
eHealth
Gesundheitsökonomie
Andere
Show AllHide
Jahr
-